Home › NDC Lookup › Ingredients › Ergocalciferol › 62135-0439-90
💊image loading
(from DailyMed)

Ergocalciferol 1.25 mg Capsule, 90-count — NDC 62135-439-90 (Billing 62135-0439-90)

by Chartwell RX, LLC · 90 CAPSULE in 1 BOTTLE

This is a package of 90 capsules of Ergocalciferol 1.25 mg Capsule from Chartwell RX, LLC, marketed since Apr 2018 and currently FDA-listed; retail pharmacies pay about $0.1136 per capsule (NADAC). It is this product's only package size.

NDC 62135-0439-90
🏷️ FDA NDC (as labeled) 62135-439-90 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 62135-439-90 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
62135 labeler · 439 product · 90 package
Package marketed since
Dec 23, 2022
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
90 EA per package
Barcode (UPC)
0362135439903
Medicaid fills, this package
502 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 62135-439-90
Product NDC 62135-439
11-digit billing NDC 62135043990
NCPDP billing unit EA — each (per item)
RxCUI 1367410
UNII VS041H42XC
UPC 0362135439903
Application # ANDA040833
SPL Set ID 6490770b-82ef-4e7c-be93-999174d4ee59
Established class (EPC) Provitamin D2 Compound
Chemical class Ergocalciferols
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-04-30
Route ORAL
Dosage form CAPSULE
Substance ERGOCALCIFEROL
TE code (Orange Book) AA · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 77202030000110
GCN Seq No 002169
GCN 94422
HICL code 000995
Ingredient (HICL) Ergocalciferol (Vitamin D2)
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C6
Therapeutic class — intermediate (HIC2) Vitamins
HIC3 code C6D
Therapeutic class — specific (HIC3) Vitamin D Preparations
AHFS code 88:16.00.00
AHFS class Vitamin D
FDB label name VITAMIN D2 1.25MG(50,000 UNIT)
FDB brand name Vitamin D2
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 002169
  • GCN: 94422
  • GPI-14 (Medi-Span): 77202030000110
  • HICL (First Databank): 000995
  • AHFS class code: 88:16.00.00
  • RxCUI (RxNorm): 1367410
Why two NDCs? The FDA registers this code as 62135-439-90 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 62135-0439-90. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Provitamin D2 Compound class.

Pharmacologic class Provitamin D2 Compound
Drug family (ATC) Vitamin D and analogues
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name VITAMIN D2 1.25MG(50,000 UNIT) Ingredient Ergocalciferol (Vitamin D2)
📖 What it is MedlinePlus · NLM

Ergocalciferol is used in the treatment of hypoparathyroidism (condition in which the body does not produce enough parathyroid hormone), refractory rickets (softening and weakening of bones that does not respond to treatment), and familial hypophosphatemia (rickets or osteomalacia caused by an inherited condition with a decreased ability to break down vitamin D in the body). Ergocalciferol is in a class of medications called vitamin D analogs. It works by helping the body to use more of the calcium found in foods or supplements.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It is vitamin D2, and it is prescribed for hypoparathyroidism, vitamin D resistant rickets, and familial hypophosphatemia. Your doctor will explain which one applies to you.
  • Take it by mouth as a capsule, exactly as your prescriber directs. Your dose is individualized, so don't change it on your own. Make sure you get enough calcium, and keep your bloo...
  • The safe range for vitamin D is narrow, and too much can raise your calcium too high. Blood calcium and phosphorus are checked every 2 weeks or more often. Bone X-rays are done mon...
  • Nausea, poor appetite, constipation, weight loss, and vague aches or weakness can signal too much vitamin D. Heavy thirst and frequent urination are also warning signs. Call me or...
📖 Read our full Ergocalciferol guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.114 $10.22 / 90 capsules
Medicaid paysCMS SDUD · 12 mo $2.08 $187.51 / 90 capsules
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2023 Jan 2026 May 2026 Sep 2026 $0.133 $0.109
▼ Down 11% over the last 13 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
62135-0439-90 You're viewing this Main listing 90 CAPSULE in 1 BOTTLE 2022-12-23 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ergocalciferol 1.25 mg 13668-0757-01 Torrent 100 capsules $0.114 AA Availability likely —
Ergocalciferol Capsules, 1.25 mg 42806-0547-01 Epic 100 capsules $0.114 AA Availability likely —
Vitamin D 1.25 mg 50268-0297-15 AvPAK 50 capsules $0.114 AA Availability likely —
Ergocalciferol 1.25 mgthis 62135-0439-90 Chartwell 90 capsules $0.114 AA Availability likely —
Vitamin D 1.25 mg 64380-0737-06 Strides 100 capsules $0.114 AA Availability likely —
Ergocalciferol 1.25 mg 69452-0151-20 Bionpharma 100 capsules $0.114 AA Availability likely —
Ergocalciferol 1.25 mg 42291-0266-01 AvKARE 100 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 43063-0711-12 PD-Rx 12 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 43353-0238-03 Aphena 3 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 50090-5844-01 A-S 8 capsules — AA FDA listed —
Vitamin D 1.25 mg 51407-0700-01 Golden 100 capsules — AA FDA listed —
Ergocalciferol Capsules, 1.25 mg 51655-0730-80 Northwind 8 capsules — AA FDA listed —
Vitamin D 1.25 mg 51655-0774-27 Northwind 12 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 60760-0152-12 St. 12 capsules — AA FDA listed —
Vitamin D 1.25 mg 61919-0702-04 DirectRX 4 capsules — AA FDA listed —
Vitamin D 1.25 mg 63187-0519-06 Proficient 6 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 63629-2447-01 Bryant 100 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 63629-7913-01 Bryant 90 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 68071-1951-02 NuCare 12 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 68071-2295-01 NuCare 100 capsules — AA FDA listed —
Ergocalciferol Capsules, 1.25 mg 68788-4042-01 Preferred 100 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 68788-4092-01 Preferred 100 capsules — AA FDA listed —
Vitamin D 1.25 mg 68788-7627-01 Preferred 100 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 70518-0177-03 REMEDYREPACK 1 capsule — AA Discontinued —
Vitamin D 1.25 mg 70518-1878-01 REMEDYREPACK 12 capsules — AA FDA listed —
Ergocalciferol Capsules, 1.25 mg 70518-3472-00 REMEDYREPACK 4 capsules — AA Discontinued —
Ergocalciferol Capsules, 1.25 mg 71205-0676-30 Proficient 30 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 71335-0062-00 Bryant 45 capsules — AA FDA listed —
Vitamin D 1.25 mg 71335-0278-00 Bryant 45 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 71335-1691-00 Bryant 45 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 71335-1699-01 Bryant 90 capsules — AA FDA listed —
Ergocalciferol Capsules, 1.25 mg 71335-2003-01 Bryant 4 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 71335-2246-01 Bryant 4 capsules — AA FDA listed —
Vitamin D 1.25 mg 71610-0552-04 Aphena 4 capsules — AA FDA listed —
Ergocalciferol 1.25 mg 71610-0712-03 Aphena 3 capsules — AA FDA listed —
Vitamin D 1.25 mg 72789-0249-01 PD-Rx 100 capsules — AA FDA listed —
Ergocalciferol (Vitamin D2) 1.25 mg 80425-0130-03 Advanced 12 capsules — AA FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2018
On the market since
Apr 2018
📍
2026
Currently FDA-listed
8 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color green
ShapeOval
ImprintA3
Size13 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Ergocalciferol inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 35SW5USQ3G
    A synthetic yellow dye used to color medicines. It helps make tablets, capsules, and liquids visually distinct so patients can easily identify their medication.
  • UNII H3R47K3TBD
    FD&C Blue No. 1 is a synthetic blue dye approved for use in foods and medicines. It serves as a colorant to give the medication its distinctive appearance and help with product identification.
  • UNII 2G86QN327L
    Gelatin is a protein derived from animal collagen, commonly used in medicines as a gelling agent and capsule material. It helps create soft or hard capsule shells that hold and release medication, and can also thicken liquid formulations.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 241ATL177A
    Soybean oil is a natural plant oil derived from soybean seeds. It's used in medicines as a solvent and carrier to help dissolve or suspend active ingredients and improve how the body absorbs them.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerChartwell RX, LLC
Application holderCHARTWELL RX SCIENCES LLC
FDA applicationANDA040833 (ANDA)
Labeler code62135
First marketedApr 2018
Product typeHuman Prescription Drug
Portfolio521 products on file

More NDCs from Chartwell RX, LLC labeler code 62135

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 27 words ▾

INDICATIONS AND USAGE Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.

⏱️ Dosage and Administration 83 words ▾

DOSAGE AND ADMINISTRATION THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. Vitamin D Resistant Rickets: 12,000 to 500,000 USP units daily. Hypoparathyroidism: 50,000 to 200,000 USP units daily concomitantly with calcium lactate 4 g, six times per day.

DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION. Calcium intake should be adequate. Blood calcium and phosphorus determinations must be made every 2 weeks or more frequently if necessary.

X-rays of the bones should be taken every month until condition is corrected and stabilized.

⛔ Contraindications 24 words ▾

CONTRAINDICATIONS Ergocalciferol Capsules, USP are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

⚠️ Warnings 31 words ▾

WARNINGS Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia. In these cases vitamin D must be strictly restricted. Keep out of the reach of children.

🤒 Adverse Reactions 100 words ▾

ADVERSE REACTIONS Hypervitaminosis D is characterized by effects on the following organ system: Renal: Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. CNS: Mental retardation. Soft Tissues: Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs.

Skeletal: Bone demineralization (osteoporosis) in adults occurs concomitantly. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism), vague aches, stiffness, and weakness. Gastrointestinal: Nausea, anorexia, constipation.

Metabolic: Mild acidosis, anemia, weight loss.

🔄 Drug Interactions ~1 min read ▾

Drug Interactions Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations. Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the drug's potential in these areas.

Pregnancy Category C Animal reproduction studies have shown fetal abnormalities in several species associated with hypervitaminosis D. These are similar to the supravalvular aortic stenosis syndrome described in infants by Black in England (1963). This syndrome was characterized by supravalvular aortic stenosis, elfin facies, and mental retardation.

For the protection of the fetus, therefore, the use of vitamin D in excess of the recommended dietary allowance during normal pregnancy should be avoided unless, in the judgment of the physician, potential benefits in a specific, unique case outweigh the significant hazards involved. The safety in excess of 400 USP units of vitamin D daily during pregnancy has not been established. Nursing Mothers Caution should be exercised when ergocalciferol is administered to a nursing woman.

In a mother given large doses of vitamin D, 25-hydroxycholecalciferol appeared in the milk and caused hypercalcemia in her child. Monitoring of the infant’s serum calcium concentration is required in that case (Goldberg, 1972). Pediatric Use Pediatric doses must be individualized (see DOSAGE AND ADMINISTRATION ).

Geriatric Use Clinical studies of ergocalciferol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. A few published reports have suggested that the absorption of orally administered vitamin D may be attenuated in elderly compared to younger individuals.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

🆘 Overdosage ~1 min read ▾

OVERDOSAGE The effects of administered vitamin D can persist for two or more months after cessation of treatment. Hypervitaminosis D is characterized by: 1. Hypercalcemia with anorexia, nausea, weakness, weight loss, vague aches and stiffness, constipation, mental retardation, anemia, and mild acidosis.

2. Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. 3.

Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Bone demineralization (osteoporosis) in adults occurs concomitantly. 4.

Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism). The treatment of hypervitaminosis D with hypercalcemia consists of immediate withdrawal of the vitamin, a low calcium diet, generous intake of fluids, along with symptomatic and supportive treatment. Hypercalcemic crisis with dehydration, stupor, coma, and azotemia requires more vigorous treatment.

The first step should be hydration of the patient. Intravenous saline may quickly and significantly increase urinary calcium excretion. A loop diuretic (furosemide or ethacrynic acid) may be given with the saline infusion to further increase renal calcium excretion.

Other reported therapeutic measures include dialysis or the administration of citrates, sulfates, phosphates, corticosteroids, EDTA (ethylenediaminetetraacetic acid), and mithramycin via appropriate regimens. With appropriate therapy, recovery is the usual outcome when no permanent damage has occurred. Deaths via renal or cardiovascular failure have been reported.

The LD 50 in animals is unknown. The toxic oral dose of ergocalciferol in the dog is 4 mg/kg.

🧬 Clinical Pharmacology 148 words ▾

CLINICAL PHARMACOLOGY The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxy- vitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization.

Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules. There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.

📦 How Supplied / Storage and Handling 91 words ▾

HOW SUPPLIED Each green, oval softgel capsule is imprinted with A3 and contains 1.25 mg (50,000 USP units vitamin D) of ergocalciferol, USP. NDC 62135-439-90 Bottles of 90 Softgel Capsules Store at 20°- 25°C (68°-77°F) [See USP Controlled Room Temperature]. Protect from light and moisture.

Dispense in a tight, light-resistant container as defined in the USP. To report SUSPECTED ADVERSE REACTIONS, contact Chartwell RX, LLC. at 1-845-232-1683 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch Manufactured by: Swiss Caps AG Kirchberg, Switzerland Manufactured for: Chartwell RX, LLC. Congers, NY 10920 Revision: 02/2023 L71168

📋 Description 191 words ▾

DESCRIPTION Ergocalciferol Capsules, USP is a synthetic calcium regulator for oral administration. Ergocalciferol is a white, colorless crystal, insoluble in water, soluble in organic solvents, and slightly soluble in vegetable oils. It is affected by air and by light.

Ergosterol or provitamin D 2 is found in plants and yeast and has no antirachitic activity. There are more than 10 substances belonging to a group of steroid compounds, classified as having vitamin D or antirachitic activity. One USP Unit of vitamin D 2 is equivalent to one International Unit (IU), and 1 mcg of vitamin D 2 is equal to 40 IU.

Each softgel capsule, for oral administration, contains Ergocalciferol, USP 1.25 mg (equivalent to 50,000 USP units of Vitamin D), in an edible vegetable oil. Ergocalciferol, also called vitamin D 2 , is 9, 10-secoergosta - 5, 7, 10 (19), 22-tetraen-3-ol , (3β, 5 Z , 7 E , 22 E ) -; (C 28 H 44 O) with a molecular weight of 396.65, and has the following structural formula: Inactive Ingredients : D&C Yellow No. 10, FD&C Blue No.

1, Gelatin, Glycerin, Purified Water, Refined Soybean Oil. image description

⚠️ Precautions 139 words ▾

PRECAUTIONS General Vitamin D administration from fortified foods, dietary supplements, self-administered and prescription drug sources should be evaluated. Therapeutic dosage should be readjusted as soon as there is clinical improvement. Dosage levels must be individualized and great care exercised to prevent serious toxic effects.

IN VITAMIN D RESISTANT RICKETS THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. When high therapeutic doses are used progress should be followed with frequent blood calcium determinations. In the treatment of hypoparathyroidism, intravenous calcium, parathyroid hormone, and/or dihydrotachysterol may be required.

Maintenance of a normal serum phosphorous level by dietary phosphate restriction and/or administration of aluminum gels as intestinal phosphate binders in those patients with hyperphosphatemia as frequently seen in renal osteodystrophy is essential to prevent metastatic calcification. Adequate dietary calcium is necessary for clinical response to vitamin D therapy. Protect from light.

📄 Package Label / Principal Display Panel 20 words ▾

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL Vitamin D Ergocalciferol Capsules, USP 1.25mg (50,000 USP Units) NDC-62135-439-90 - 90s Bottle Label image description

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
502
Units reimbursed last 4 qtrs
2.3K
Gross reimbursed last 4 qtrs
$4.8K
Avg / prescription
$9.49
Avg / unit
$2.0834
Latest quarter Q1 2026
125Rx
Medicaid pays / ea
$2.0834
gross reimbursed
vs
NADAC / ea
$0.1136
acquisition cost
=
Spread
+$1.9698
+1734% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
70% FFS 30% MCO
Fee-for-service · 350 Rx Managed care · 152 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 669 units · 3.4 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 85 units · 0.7 per 100k residents OH Pennsylvania: no data reported PA New Jersey: 448 units · 4.8 per 100k residents NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 96 units · 1.5 per 100k residents MO Kentucky: no data reported KY West Virginia: 53 units · 3.0 per 100k residents WV Virginia: 181 units · 2.1 per 100k residents VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 700 units · 15.3 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 55 units · 0.2 per 100k residents FL
Units reimbursed · per 100k residents
0.215.3
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Louisiana 15.3 /100k
2 New Jersey 4.8 /100k
3 New York 3.4 /100k
4 West Virginia 3.0 /100k
5 Virginia 2.1 /100k
6 Missouri 1.5 /100k
7 Ohio 0.7 /100k
8 Florida 0.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
← 62135-0438-47 · Chartwell 62135-0440-31 · Chartwell →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.